Exciva

Exciva is a clinical-stage biotech company developing therapeutics for neuropsychiatric symptoms of dementia, specifically targeting agitation and aggression in Alzheimer’s disease. Its lead program, Deraphan, is currently in Phase 2/3 clinical trials to improve the quality of life for patients and caregivers. The company focuses on bridging the gap in dementia care through pharmaceutical research and rigorous clinical testing.